Navigation Links
Galvus Soon To Be Seen On European Shelves

Galvus, a drug from Novartis AG has been given the green light from the European Medicines Agency. Now open to the European market, Galvus has nevertheless still no access to its American counterpart.

The decision by a committee of experts at the European Medicines Agency came soon after Novartis said it would not be ready to resubmit Galvus to U.S. regulators until mid-2009, due to a request for more safety data.

Galvus is said to work in a similar way to Merck & Co. Inc.s recently launched Januvia, though the latters path to market has been delayed by worries over skin toxicity.

Both Galvus and Januvia are so-called DPP-4 inhibitors, which are designed to enhance the body's own ability to lower elevated blood sugar and could become an important new way to control type 2 diabetes - the most common form of the disease.

The drugs' manufacturers and many analysts believe DPP-4 drugs could sell like hot cakes because they are not associated with weight gain, a major side effect of some established diabetes drugs. Galvus is being recommended in the European Union for use in combination with other common oral diabetes medicines -metformin, a thiazolidinedione (TZD) or a sulfonylurea (SU).

Says Novartis's global head of pharma development, James Shannon: "Many type 2 diabetes patients need more than one treatment to bring their blood sugar levels under control, therefore the efficacy and tolerability of Galvus in combination with other medicines is especially significant.

As of now, Novartis expects to resubmit its Galvus diabetes treatment for U.S. approval around the middle of 2009, while starting a new study later this year. "It (the study) will likely take until at least the end of 2008 to complete. And then we would propose to resubmit the dossier to the FDA sometime in mid-2009", Shannon was quoted.


'"/>




Page: 1

Related medicine news :

1. Lung Cancer Deaths Declining In Men But Not Women In European Countries
2. Record Growth Of Soya-Based Dairy Alternatives Over The Past Year In European Markets
3. European Countries To Fund $4 Billion For Vaccination For Poor Children’
4. Nanotechnology Revolution To Be Spearheaded By European Union
5. Detection of Weak strains of bird flu virus – Target of European Unio
6. Europe On High Bird Flu Alert: European Commission
7. Slovenia, Bulgaria, Greece Face Bird Flu Threat: European Union
8. Heart Brakes: Hearts in European Union Invite Health Attention
9. European Union: Poultry producers Need Aid to Survive Bird flu crisis
10. 5th European Breast Cancer Conference Talks about Everything from Patient to Oncologist
11. Control And Prevention Of Three Diseases To Be Discussed: European Commission
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Galvus Soon Seen European Shelves

(Date:8/28/2014)... Catalent Pharma Solutions, the leading ... solutions for drugs, biologics and consumer health products, ... Supply Services, and Chris Greco, Manager, Comparator and ... for Active Control Clinical Trials” at the forthcoming ... on the 9th – 10th September, 2014 in ...
(Date:8/28/2014)... researchers place glue directly on the nerve stumps, but ... and allows glue to easily invade the nerve ends. ... to insert the nerve ends into the conduit because ... Xiangdang Liang and co-workers from the General Hospital of ... technique and defined the best parameters for its use ...
(Date:8/28/2014)... an investigational vaccine to prevent Ebola virus disease will ... and Infectious Diseases (NIAID), part of the National Institutes ... human testing of a vaccine co-developed by NIAID and ... and ability to generate an immune system response in ... Clinical Center in Bethesda, Maryland. , The study is ...
(Date:8/28/2014)... treated with nasal septum cells. Researchers at the University ... taken from the nasal septum are able to adapt ... thus repair articular cartilage defects. The nasal cartilage cells, ... is associated with the expression of so-called HOX genes. ... published the research results together with the report of ...
(Date:8/28/2014)... A subset of patients with stage III colon ... therapy, according to a new study in ... the American Gastroenterological Association. , When added to the ... irinotecan therapy improved overall survival rates for patients with ... in about 10 to 20 percent of colorectal cancers. ...
Breaking Medicine News(10 mins):Health News:Critical Path Sourcing Strategies for Global Clinical Trials Presented by Catalent Experts at US Clinical Trials Supply Conference 2Health News:NIH to Launch human safety study of Ebola vaccine candidate 2Health News:NIH to Launch human safety study of Ebola vaccine candidate 3Health News:NIH to Launch human safety study of Ebola vaccine candidate 4Health News:NIH to Launch human safety study of Ebola vaccine candidate 5Health News:From nose to knee: Engineered cartilage regenerates joints 2Health News:Drug shows promise for subset of stage III colon cancer patients 2
... Offers Hope to Millions of Couples Seeking a Better Sex,Life, ... relieved by the,preliminary results of a new study that demonstrates ... lives. The exercises take,just 5 minutes a day but the ... who followed the simple PelvicToner exercise,programme reported an improved sex ...
... to farms, particularly to barns and farm milk, while ... to a group of German researchers, who will present ... Conference in Toronto on Wednesday, May 21., In a ... 59 non-farming mothers, the researchers believe they have proved ...
... their Prescription History, WALNUT CREEK, Calif., May ... ) announced today a new collaboration with,Google Health ... between,patients and providers. Working with Google, Longs will ... customers with the ability to import their,prescription information ...
... 18, 2008 TAP Pharmaceutical Products Inc. today reported ... new drug TAK-390MR, the first proton pump inhibitor (PPI) ... patients with erosive esophagitis (EE) and in maintenance of ... Disease Week (DDW) annual meeting in San Diego. , ...
... over T-cell counts for monitoring HIV treatment , ... can help identify those whose treatment will succeed or ... from pharmacy records, works at least as well as ... the immune system, according to research published in PLoS ...
... initiation and progression of prostate cancer have eluded ... researchers have identified a specific gene expression profile ... for future treatments. The findings, published in BioMed ... genes that are differentially expressed in certain prostate ...
Cached Medicine News:Health News:Is Female Sexual Dysfunction a Myth? 2Health News:Farm moms may help children beat allergies 2Health News:Longs Drugs Partners With Google on the Launch of Google Health 2Health News:TAK-390MR Phase 3 data presented at Digestive Disease Week 2Health News:TAK-390MR Phase 3 data presented at Digestive Disease Week 3Health News:TAK-390MR Phase 3 data presented at Digestive Disease Week 4Health News:Monitoring whether patients take medicines can help anticipate HIV treatment failure in Africa 2Health News:Monitoring whether patients take medicines can help anticipate HIV treatment failure in Africa 3Health News:Monitoring whether patients take medicines can help anticipate HIV treatment failure in Africa 4Health News:Monitoring whether patients take medicines can help anticipate HIV treatment failure in Africa 5Health News:Mapping of prostate cancer genes opens the door to new treatments 2
(Date:8/28/2014)... Colo. , Aug. 28, 2014   Venaxis, ... company focused on obtaining FDA clearance for and commercializing ... blood test for aiding in identifying children, adolescent, and ... at low risk for appendicitis, today announced it will ... Renshaw 16 th Annual Global Investment Conference being ...
(Date:8/28/2014)... YORK , Aug. 28, 2014 ... new market research report is available ... Multiforme Therapeutics in Asia-Pacific Markets to ... High Unmet Need in Newly Diagnosed ... http://www.reportlinker.com/p02343492/Glioblastoma-Multiforme-Therapeutics-in-Asia-Pacific-Markets-to-2020---Novel-Therapeutic-Approaches-Target-High-Unmet-Need-in-Newly-Diagnosed-and-Recurrent-GBM.html ...
(Date:8/28/2014)... MAHWAH, N.J. , Aug. 28, 2014  Stryker Orthopaedics, ... Champions Tour, is bringing its message of joint health to ... Playoffs this week at the Deutsche Bank Championship. The company,s ... in the "Fairway Fan Zone on 9" at the TPC ... Thursday, August 28 th .    At the ...
Breaking Medicine Technology:Venaxis to Present at September Investor Conferences 2Venaxis to Present at September Investor Conferences 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 6Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 7Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 8Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 9Stryker, Official Joint Replacement Products Of The PGA TOUR, Heads To Boston For The Deutsche Bank Championship 2Stryker, Official Joint Replacement Products Of The PGA TOUR, Heads To Boston For The Deutsche Bank Championship 3Stryker, Official Joint Replacement Products Of The PGA TOUR, Heads To Boston For The Deutsche Bank Championship 4Stryker, Official Joint Replacement Products Of The PGA TOUR, Heads To Boston For The Deutsche Bank Championship 5
... 2007 - OSI,Pharmaceuticals, Inc. (Nasdaq: OSIP) announced ... of Clinical Oncology show that,adding Tarceva(R) (erlotinib) ... as first-line,therapy to patients with advanced pancreatic ... National Cancer Institute of Canada (NCIC),formed the ...
... STRASBOURG, France and VANCOUVER, April 26, 2007,/PRNewswire-FirstCall/ ... pharmaceutical and medical device company, announced that,the ... examining the,Vascular Wrap(TM) Paclitaxel-Eluting Mesh ("Vascular Wrap(TM)"),will ... in Europe. The,two-year study examined the safety ...
Cached Medicine Technology:OSI Pharmaceuticals Announces Pivotal Phase III Tarceva Study,Published in the Journal of Clinical Oncology Showed Survival,Improvement in Patients with Pancreatic Cancer 2OSI Pharmaceuticals Announces Pivotal Phase III Tarceva Study,Published in the Journal of Clinical Oncology Showed Survival,Improvement in Patients with Pancreatic Cancer 3OSI Pharmaceuticals Announces Pivotal Phase III Tarceva Study,Published in the Journal of Clinical Oncology Showed Survival,Improvement in Patients with Pancreatic Cancer 4Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 2Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 3Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 4Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 5Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 6Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium 7
Designed for simple operation, the Model 515B pulse oximeter is ideal for use in any clinical setting; from emergency hospital transport to continuous monitoring in Anesthesia, Intensive Care and Gen...
... The Models 512 and 513 handheld ... This advanced technology is able to ... resolutions and speeds of 100 times ... in improved pulse oximeter performance during ...
... Whether it's for an emergency situation, bedside ... Handheld Capnograph / Pulse Oximeter delivers accurate ... This portable, handheld monitor now contains Nellcors ... compatible with OxiMax sensors. The NPB-75 monitor ...
The new Nellcor N-45 Handheld Pulse Oximeter is compatible with our complete line of OxiMax Pulse Oximetry Sensors, so clinicians have the convenience of Nellcors most advanced sensor technology in a...
Medicine Products: